Join
Live feed
·
PRReleasevia Quantisnow
Lexicon Pharmaceuticals Inc. logo

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

ByQuantisnow·Wall Street's wire, on your screen.
LXRX· Lexicon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LXRX (Lexicon Pharmaceuticals Inc.) and more on Quantisnow.